JP2010523670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523670A5 JP2010523670A5 JP2010503045A JP2010503045A JP2010523670A5 JP 2010523670 A5 JP2010523670 A5 JP 2010523670A5 JP 2010503045 A JP2010503045 A JP 2010503045A JP 2010503045 A JP2010503045 A JP 2010503045A JP 2010523670 A5 JP2010523670 A5 JP 2010523670A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament according
- optionally substituted
- alkyl
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92289907P | 2007-04-10 | 2007-04-10 | |
| PCT/US2008/004573 WO2008124161A1 (en) | 2007-04-10 | 2008-04-09 | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013194611A Division JP2014034576A (ja) | 2007-04-10 | 2013-09-19 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523670A JP2010523670A (ja) | 2010-07-15 |
| JP2010523670A5 true JP2010523670A5 (cg-RX-API-DMAC7.html) | 2011-05-26 |
Family
ID=39627802
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503045A Pending JP2010523670A (ja) | 2007-04-10 | 2008-04-09 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
| JP2013194611A Pending JP2014034576A (ja) | 2007-04-10 | 2013-09-19 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
| JP2014059561A Pending JP2014139217A (ja) | 2007-04-10 | 2014-03-24 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013194611A Pending JP2014034576A (ja) | 2007-04-10 | 2013-09-19 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
| JP2014059561A Pending JP2014139217A (ja) | 2007-04-10 | 2014-03-24 | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
Country Status (31)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| HRP20130902T1 (hr) * | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| NZ608667A (en) * | 2005-10-07 | 2014-08-29 | Exelixis Inc | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| RS53020B (sr) * | 2007-04-11 | 2014-04-30 | Exelixis Inc. | Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera |
| CA2734489C (en) * | 2008-08-20 | 2016-11-08 | Southern Research Institute | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2010022126A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP5731976B2 (ja) | 2008-08-20 | 2015-06-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用 |
| WO2011100319A1 (en) | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
| US20130156768A1 (en) * | 2010-08-26 | 2013-06-20 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| CA2812089C (en) | 2010-09-14 | 2020-02-18 | Exelixis Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| US9441013B2 (en) * | 2011-05-17 | 2016-09-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanocortin 1 receptor ligands and methods of use |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| US20140298493A1 (en) * | 2011-07-28 | 2014-10-02 | Somasekar Seshagiri | PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model |
| WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| KR20140096083A (ko) | 2011-11-01 | 2014-08-04 | 엑셀리시스, 인코포레이티드 | 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ（3｛［（3｛［2클로로5（메톡시）페닐］아미노｝퀴녹살린2일）아미노］설포닐｝페닐）2메틸알라닌아미드 |
| JP6126615B2 (ja) * | 2011-11-11 | 2017-05-10 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| US20150010545A1 (en) * | 2011-12-27 | 2015-01-08 | Kadmon Corporation, Llc | Methods for treatment of breast cancer nonresponsive to trastuzumab |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
| US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| AU2013299841B8 (en) | 2012-08-07 | 2017-01-05 | Array Biopharma Inc. | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| CU24522B1 (es) * | 2016-08-15 | 2021-06-08 | Pfizer | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS |
| JP7027699B2 (ja) * | 2017-05-09 | 2022-03-02 | 住友ゴム工業株式会社 | タイヤトレッドおよびタイヤ |
| MX2020008015A (es) | 2018-01-31 | 2020-10-16 | Deciphera Pharmaceuticals Llc | Terapia de combinación para el tratamiento de la mastocitosis. |
| EP3746059A1 (en) | 2018-01-31 | 2020-12-09 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR102473372B1 (ko) | 2018-03-19 | 2022-12-05 | 다이호야쿠힌고교 가부시키가이샤 | 알킬황산나트륨을 포함하는 의약 조성물 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| NZ784949A (en) | 2019-08-12 | 2025-09-26 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors |
| US12486246B2 (en) | 2019-12-10 | 2025-12-02 | The Trustees Of Indiana University | Replication protein A (RPA)-DNA interaction inhibitors |
| KR20250057151A (ko) | 2019-12-30 | 2025-04-28 | 데시페라 파마슈티칼스, 엘엘씨 | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물 |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| KR102195221B1 (ko) | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
| CN111358952B (zh) * | 2020-04-15 | 2022-03-15 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种抗肿瘤药物组合物及其制剂和应用 |
| CN118678960A (zh) * | 2021-11-18 | 2024-09-20 | 安可诺瓦治疗公司 | 用于治疗癌症的方法和组合物 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| ES2400339T3 (es) * | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| EP1718645A1 (en) * | 2004-02-18 | 2006-11-08 | Warner-Lambert Company LLC | 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones |
| US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
| JP5216958B2 (ja) * | 2005-07-06 | 2013-06-19 | 株式会社三和技術総合研究所 | 漏洩電流検出装置及び漏洩電流検出方法 |
| HRP20130902T1 (hr) * | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| NZ608667A (en) * | 2005-10-07 | 2014-08-29 | Exelixis Inc | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MY146420A (en) * | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| RS53020B (sr) * | 2007-04-11 | 2014-04-30 | Exelixis Inc. | Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera |
| AU2008239655B2 (en) | 2007-04-11 | 2013-06-20 | Exelixis, Inc. | Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer |
| AU2008239596B2 (en) | 2007-04-11 | 2013-08-15 | Exelixis, Inc. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer |
| TW201018685A (en) * | 2008-09-30 | 2010-05-16 | Exelixis Inc | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
-
2008
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/en not_active Ceased
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/en active Active
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/me unknown
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko not_active Expired - Fee Related
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 US US12/595,219 patent/US8513266B2/en not_active Expired - Fee Related
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 CA CA2683641A patent/CA2683641C/en not_active Expired - Fee Related
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 RS RS20130384A patent/RS52939B/sr unknown
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
-
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
-
2013
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
-
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending